Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study.
Br J Haematol
; 201(5): 935-939, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36846905
3.
Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias.
Br J Haematol
; 199(4): 520-528, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041779
4.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
5.
Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series.
Clin Transplant
; 36(3): e14541, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34797567
6.
Evaluation of subcutaneous daratumumab injections in the ambulatory care setting.
J Oncol Pharm Pract
; 28(8): 1819-1825, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647506
7.
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Cancer
; 127(11): 1816-1826, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33735504
8.
Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(5): 876-883, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31785375
9.
Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Curr Oncol Rep
; 21(4): 35, 2019 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30848394
10.
Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.
J Oncol Pharm Pract
; 25(5): 1253-1257, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30005587
11.
Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Blood
; 127(19): 2275-80, 2016 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26907632
12.
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Haematologica
; 103(7): 1218-1228, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29622655
13.
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable.
Clin Lymphoma Myeloma Leuk
; 24(5): e217-e225, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38369437
14.
Salvage Therapies including Retreatment with BCMA-directed Approaches Following BCMA CAR-T Relapses for Multiple Myeloma.
Blood Adv
; 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38429087
15.
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy.
Blood Adv
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38574299
16.
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Clin Cancer Res
; 30(5): 1009-1021, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109209
17.
Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma.
Leuk Lymphoma
; 64(6): 1186-1193, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37096638
18.
Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Transplant Cell Ther
; 29(8): 504.e1-504.e7, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244643
19.
Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Transplant Cell Ther
; 29(6): 350-355, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36933659
20.
Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Curr Probl Cancer
; 47(3): 100953, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807996